| Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798) |
|---|
| 01/22/2003 | CN1391933A Medicinal composition for improving memory |
| 01/22/2003 | CN1391928A Medicine Qingyedan for curing hepatitis and its preparing method |
| 01/22/2003 | CN1391918A Composition for curing hepatopathy |
| 01/22/2003 | CN1391916A Gastric ulcer treating capsule |
| 01/22/2003 | CN1391909A Compound combined medicine capable of improving human health and its producing method |
| 01/22/2003 | CN1391908A External applied paste as antidiarrheal |
| 01/22/2003 | CN1391905A Microbial preparation for curing intestinal diseases |
| 01/22/2003 | CN1391899A Aseptic freeze-dried prostaglandin injection and its preparing method and use |
| 01/22/2003 | CN1391895A New oral dosage form of Anethol Trithione |
| 01/22/2003 | CN1391894A Silybin injection containing cyclo dextrin or its derivatives |
| 01/22/2003 | CN1099425C 新的肽衍生物 New peptide derivatives |
| 01/22/2003 | CN1099289C Microbial preparation for improving intenstinal ecological balance and its process |
| 01/21/2003 | US6509443 Amino acid residue located at position 63 of native-sequence human Insulin like Growth Factor-I is replaced with an alanine residue or amino acid residues at positions 1 and 70 are replaced with serine and valine respectively |
| 01/21/2003 | US6509376 Utilization of dialkyfumarates |
| 01/21/2003 | US6509368 Use of catechol derivatives as proteinase inhibitors |
| 01/21/2003 | US6509364 Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2α antagonists |
| 01/21/2003 | US6509357 1-aryl or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 01/21/2003 | US6509351 A method of inhibiting TNF- alpha in a patient in need thereof which comprises administering to said patient an effective amount of a compound for inflamation |
| 01/21/2003 | US6509346 Chemokine receptor antagonists and methods of use therefor |
| 01/21/2003 | US6509340 Amide and urea derivatives as 5-HT reuptake inhibitors and as 5-HT1B/1D ligands |
| 01/21/2003 | US6509339 Gastrointestinal disorders; cardiovascular disorders |
| 01/21/2003 | US6509328 Glutamate receptor antagonists |
| 01/21/2003 | US6509165 Detecting the ability of proinsulin peptide to preferentially stimulate the T-cells of diabetic subjects by measuring the ability of the T-cells to proliferate or ability of the T-cells to produce cytokines |
| 01/21/2003 | US6509154 Product comprising at least a double stranded RNA combined with at least an antiviral agent |
| 01/21/2003 | US6509028 Methods and compositions for treating pain of the mucous membrane |
| 01/21/2003 | US6509015 Human antibodies that bind human TNFa |
| 01/21/2003 | US6509005 Nonozone depleting stable aerosol; treating nausea and vomiting associated with chemotherapy; muscle spasticity, pain, anorexia associated with AIDS wasting syndrome, epilepsy, glaucoma, bronchial asthma and mood disorders |
| 01/17/2003 | CA2407295A1 Transgenic non-human mammal |
| 01/16/2003 | WO2003004613A2 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | WO2003004608A2 Drug metabolizing enzymes |
| 01/16/2003 | WO2003004511A2 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
| 01/16/2003 | WO2003004503A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | WO2003004501A2 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | WO2003004498A1 Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 01/16/2003 | WO2003004497A1 Novel heterocyclic compound |
| 01/16/2003 | WO2003004493A1 Novel compounds, their preparation and use |
| 01/16/2003 | WO2003004492A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | WO2003004487A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | WO2003004480A2 Substituted piperazine and diazepanes as histamine h3 receptor agonists |
| 01/16/2003 | WO2003004467A2 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | WO2003004096A2 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | WO2003004046A2 Use of xaa-pro peptidases for the treatment of substance p-related disorders |
| 01/16/2003 | WO2003004023A1 1-alkyl-2-aryl-benzimidazole derivatives, their use for producing medicaments and pharmaceutical preparations containing said derivatives |
| 01/16/2003 | WO2003004007A2 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2002096394A3 Pharmaceutical composition containing stool softener such as polaxamer and enteric coated particles of bisacodyl |
| 01/16/2003 | WO2002085387A3 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
| 01/16/2003 | WO2002085386A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
| 01/16/2003 | WO2002085385A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| 01/16/2003 | WO2002078676A3 Enteric ketoacid salts and amino acids |
| 01/16/2003 | WO2002072527A3 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 01/16/2003 | WO2002056010A3 Methods for the treatment of ibs |
| 01/16/2003 | WO2002051837A3 Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands |
| 01/16/2003 | WO2002050034A3 Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| 01/16/2003 | WO2002020813A3 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | WO2001092490A3 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001089546A3 Treatment for irritable bowel syndrome and related conditions |
| 01/16/2003 | WO2001062705A3 Aminoalcohol derivatives |
| 01/16/2003 | WO2001058954A9 Trade molecules and uses related thereto |
| 01/16/2003 | US20030013875 3-azabicyclo[3.1.0]hexane derivatives useful in therapy |
| 01/16/2003 | US20030013850 Antiinflammatory agents |
| 01/16/2003 | US20030013770 Aminobenzophenones as inhibitors of il 1b and tnf |
| 01/16/2003 | US20030013754 Antiinflamamtory agents |
| 01/16/2003 | US20030013733 Antihistamines, sleep disorders, central nervous system disorders |
| 01/16/2003 | US20030013730 Preventing diarrhea |
| 01/16/2003 | US20030013718 Phthalazine derivatives for treating inflammatory diseases |
| 01/16/2003 | US20030013717 Cyclooxygenase inhibitor |
| 01/16/2003 | US20030013716 Pyrazino-pyridazine derivatives as ligands for gaba receptors |
| 01/16/2003 | US20030013713 Compounds as PDE IV and TNF-inhibitors |
| 01/16/2003 | US20030013707 Enzyme inhibitor |
| 01/16/2003 | US20030013704 Adamantane derivatives |
| 01/16/2003 | US20030013693 Method and composition for treatment of inflammatory conditions |
| 01/16/2003 | US20030013691 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/16/2003 | US20030013676 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | US20030013668 Antiarthritic agents; inflammatory bowel disease; multiple sclerosis |
| 01/16/2003 | US20030013665 Novel macrolide antibiotics |
| 01/16/2003 | US20030013652 Releasing moderators for inflammation |
| 01/16/2003 | US20030013642 Hemoglobin-haptoglobin complexes |
| 01/16/2003 | US20030013081 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012782 Method and composition for altering a T cell mediated pathology |
| 01/16/2003 | CA2453075A1 Drug metabolizing enzymes |
| 01/16/2003 | CA2452609A1 Thiazole benzamide derivatives and pharmaceutical compositions for inhibiting cell proliferation, and methods for their use |
| 01/16/2003 | CA2452603A1 Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases |
| 01/16/2003 | CA2452597A1 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 01/16/2003 | CA2452590A1 Morpholine-bridged pyrazolopyridine derivatives |
| 01/16/2003 | CA2452392A1 Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
| 01/16/2003 | CA2452241A1 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | CA2451738A1 Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals using 2-amino-2'-deoxyadenosine |
| 01/16/2003 | CA2451606A1 (hetero) aryl substituted benzofurans as 5-ht ligands |
| 01/16/2003 | CA2451395A1 Novel pgc-1 isoforms and uses therefor |
| 01/16/2003 | CA2451360A1 Method and composition for prolonging the residence time of drugs in the gut |
| 01/16/2003 | CA2448913A1 Sulfone containing bicyclic aromatic ring compounds, their preparation and use as nicotinic acetyl-chloine receptors |
| 01/15/2003 | EP1275638A1 Combination therapy for the treatment of immunological disorders |
| 01/15/2003 | EP1274861A1 Compositions and methods for identifying and targeting cancer cells |